- Home
- / Uk & Ireland solutions /
- Health Economics and Outcomes Research
Health Economics & Outcomes Research in UK & Ireland
- Home
- / UK & Ireland Solutions /
- Health Economics and Outcomes Research
Health economics & outcomes research
Evaluating and characterising value and budget impact is a critical step in successfully navigating reimbursement processes.
Health Economics and Outcomes Research (HEOR) plays a critical role in building the evidence package required to support reimbursement. For the rare disease space, this can be especially challenging as there are often shorter-term single-arm clinical trials and variations seen in what is considered as standards of care. Economic modelling, and the data analytics that sit alongside, provides an ideal framework to consider the sensitivities and potential impacts of imperfect information, and helps prompt communication of broader value argumentation. One of the most impactful uses of HEOR modelling is as a strategic planning tool to consider data gaps and value profiling early in a product’s lifecycle, influencing global evidence generation for reimbursement.
What we can offer you
Our experienced team uses the latest economic modelling techniques to develop and adapt models based on your bespoke evidence needs. This can involve a simple decision tree, a partitioned survival model, a Markov health state transition model, and in some cases a patient-level simulation approach. Methodology will always be based on an expert assessment of your unique commercial needs.
Our in-house Health Economists are experts at building models and offer expertise in Artificial Intelligence and Machine Learning. Our HEOR team is here to help you develop the most robust and compelling economic arguments to support your HTA strategy and submission.
Our services
- Cost effectiveness & Budget Impact Modelling
- Early Model Review
- Disease area and payer landscape insights
- Evidence gap analysis and mitigation plants
- Treatment pathway and model input validation
- KOL engagement advisory boards
- Evidence Generation Support
- Stakeholder Engagement & Payer negotiations
- Guidance on pricing strategies
- HTA modelling Building models for you from scratch or repurposing and adapting existing models
Delivering impact through excellence
Results speak louder than words. At Kintiga, our track record of success demonstrates our ability to deliver impactful market access strategies that align with your ambitions.
Let’s have a chat
We pride ourselves to have a personal relationship with our network of stakeholders, opinion leaders and clients, and we would love to get to know you as well. Feel free to reach out for a chat.
Julia Sus
Director, Market Access, UK
Claire Blaney
Director Market Access & Pricing Strategy Ireland
Priscila Mazzola
Director, Head of Value Communication in Value Communication
Ben Hendry
Director, Business Development UK & Ireland
Featured case studies
Delivering a Successful SMC Re‑Submission Through Strategic Alignment and Rapid Cross‑Functional Execution
Faster, Fairer, Broader: What NICE’s 2025–26 Annual Report Means for Market Access
NICE’s New Rulebook for Obesity Health Economics: What PMG50 Means for Modellers
PMI Pharma Summit
NICE Conference 2026
Poster Presentation: Increased trends of self-optimised submissions to NICE (HTA 199)
Our expertise:
UK and Ireland Access Consultancy
Our UK and Ireland team provide tailored strategic guidance and end-to-end support across development, launch, and lifecycle management, aligned with NICE, SMC, AWMSG, and NCPE pathways and evolving HTA expectations.
UK and Ireland Market Access Pathways
Success starts with a clear launch pathway. Kintiga offers UK and Ireland expertise, supporting NICE, SMC, AWMSG, and NCPE submissions with strong evidence alignment, payer negotiation, and stakeholder engagement to drive positive outcomes.
EU HTA Strategy Support
With extensive NICE submission experience, Kintiga is well positioned to support Joint Clinical Assessments, offering integrated solutions from JSC advice to JCA reporting for successful EU HTA outcomes.
Health Economics and Outcomes Research
Our Health Economists build and adapt economic models for the UK and Ireland, integrating local data, comparators, and care pathways. We also develop early pricing and access models to guide investment and evidence strategies aligned with payer expectations.
Pricing Strategy
Kintiga analyses pricing landscapes and benchmarks competitors to shape early pricing strategies. We integrate value messaging and design long-term frameworks like risk-sharing and managed entry agreements to ensure sustainable UK and Ireland market access.
Policy and Systems Navigation
Kintiga monitors policy changes across NHSE, DoH, HSE, and regional bodies to assess their impact on your product. We provide strategic engagement with key institutions and support managed access, conditional reimbursement, and policy initiatives to optimise market entry and sustainability.
Contact us
Ready to unlock your product’s potential in Europe’s complex healthcare landscape? Contact Kintiga today to discover how our market access strategy expertise can drive measurable impact for your product.
